New antibiotic most effective against MRSA and Staph bacteria
(1888PressRelease) Tetracycline-ABC is a new antibiotic that can kill a broad range of drug-resistant bacteria -- most effective against MRSA and Staph bacteria.
A new broad spectrum antibiotic is capable of killing bacteria that have gained resistance to many of the current classes of antibiotics. The new antibiotic is needed by physicians who are running out of effective treatments for many infections because even the strongest available antibiotics no longer kill the most-deadly bacteria which infect more people each year. There is a new solution to this problem. The solution is a new antibiotic which uses a mechanism of action not previously exploited to kill bacteria.
The new antibiotic, called Tetracycline-ABC, has been found to kill a wide range of bacteria, including drug-resistant bacteria that no longer respond to existing antibiotics.
Feedback from users during the past 3 years indicates that the new antibiotic will be more than 98% effective against MRSA and Staph bacteria.
MRSA and Staph infections often result from minor cuts, scrapes and burns that get infected. Infections sometimes appear spontaneously on the skin of people having only casual contact with other people who have the bacteria on their skin. MRSA infection is a growing health issue in athletic programs, worldwide.
MRSA and Staph infections are increasing in hospitals, along with infections from Klebsiella pneumoniae and E. coli bacteria.
The new antibiotic contains tetracycline. Tetracycline is historically the most-prescribed and best-known antibiotic. The strong effectiveness of the new antibiotic results from the use of a new dual-carrier drug delivery formulation combined with tetracycline. Because of the dual-carrier effects, these products are effective in ways not previously possible with other tetracycline products.
The new antibiotic is the only liquid tetracycline product on the market. Previous attempts by other pharmaceutical companies to market tetracycline topical products were not successful because of the short shelf life of tetracycline in liquid and ointment forms. Phillips Company solved this problem by using a formulation that retards the oxidation of the dimethyl groups that are part of the tetracycline molecule.
Bacterial infections are broadly classified as Gram-positive or Gram-negative infections. Tetracycline-ABC is strongly effective against both Gram-positive and Gram-negative bacteria. Many other antibiotics are mostly effective against either Gram-positive or Gram-negative bacteria, but not both. MRSA and Staph are Gram-positive bacteria. E coli is a Gram-negative bacteria.
The path to formulation and development of this new antibiotic spanned more than five years of effort. The new antibiotic has been field tested and marketed to physicians, pharmacy outlets and to the public. This broad field test was done to search for any indication of the development of antibiotic resistance to the effectiveness of the new product. This evaluation found that Tetracycline-ABC is able to kill methicillin-resistant Staphylococcus aureus (or MRSA) and other drug resistant bacteria with no evidence of resistance even after unrestrained use by the public.
The reason the new antibiotic seems unlikely to allow bacteria to develop resistance is that Tetracycline-ABC uses two mechanisms of action whereas other antibiotics use only one mechanism of action. Most antibiotics use a chemical or biochemical mechanism of action. The new antibiotic uses both a biochemical and a physical mechanism of action. The physical mechanism of action is designed to defeat the bacteria's eflux capability.
Eflux is the pump-out capability of a bacteria cell to resist the effectiveness of an antibiotic. Over many generations, some bacteria develop a stronger eflux capability. This is one way some types of bacteria evolve and create a resistance to antibiotics. The new antibiotic is designed to defeat the bacteria's eflux capability and prevent bacteria from developing resistance to the killing and healing effectiveness of Tetracycline-ABC.
The new antibiotic comes at a time when pharmaceutical firms have been reluctant to spend millions of dollars developing new antibiotics. During the past 15 years, the market lifetime of most antibiotics has been shortened by bacteria that developed resistance to the effectiveness of those antibiotics after only a few years of widespread use. This has resulted in a shortage of new and more effective antibiotics.